

Apollo Hospitals Enterprise Limited
Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaiapuram, Chennai - 28, Tamil Nadu
Tel: +91-44-28290956, Fax: +91-44-28290956
Email: investor.relations@apollohospitals.com, Website : www.apollohospitals.com



(Rs. in Lakhs, except per share data)

Extract of Statement of Unaudited Financial Results for the Three & Six Months Ended September 30, 2020

Standalone						Consolidated						
Particulars	Three months ended 30/09/2020	Preceding Three months ended 30/06/2020	Corresponding Three months ended 30/09/2019	Year to date figures for current period ended 30/09/2020	Year to date figures for previous period ended 30/09/2019	Previous year ended 31/03/2020	Three months ended 30/09/2020	Preceding Three months ended 30/06/2020	Corresponding Three months ended 30/09/2019	Year to date figures for current period ended 30/09/2020	Year to date figures for previous period ended 30/09/2019	Previous year ended 31/03/2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total Income from Operations (net)	2,41,924	1,96,321	2,46,752	4,38,244	4,70,146	9,80,534	2,77,204	2,17,922	2,84,425	4,95,125	5,42,600	11,27,377
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	3,953	(18,592)	14,035	(14,639)	26,117	51,801	3,015	(26,701)	13,365	(23,686)	22,805	45,869
Net Profit / (Loss) for the period (before Tax, after Exceptional and/or Extraordinary Items)	3,844	(18,592)	14,035	(14,748)	26,117	68,236	6,560	(26,701)	13,365	(20,142)	22,805	65,699
Net profit / (Loss) for the period after tax (after Exceptional and Extraordinary items)	3,252	(14,911)	9,060	(11,659)	16,991	47,025	5,899	(22,626)	8,311	(16,727)	13,226	43,180
Total Comprehensive Income for the period (comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)	2,824	(15,072)	9,029	(12,248)	17,095	47,100	5,549	(22,782)	7,763	(17,232)	12,817	43,120
Paid up Equity Share Capital (Face value of Rs.5/- each)						6,956						6,956
Other Equity						3,91,897						326209
Earnings Per Share of Rs. 5/- each												
Basic	*2.34	*(10.72)	*6.51	*(8.38)	*12.21	33.80	*4.33	*(14.96)	*6.20	*(10.63)	*10.31	32.70
Diluted	*2.34	*(10.72)	*6.51	*(8.38)	*12.21	33.80	*4.33	*(14.96)	*6.20	*(10.63)	*10.31	32.70
Debt Equity Ratio				0.83	0.96	0.82						
Debt Service Coverage Ratio				0.77	2.53	2.92						
Interest Service Coverage Ratio				2.53	5.82	4.27						
Network				3,69,495	3,52,858	3,85,570						
Paid up Debt Capital				50,000	50,000	50,000						
Debiture Redemption Reserve				12,500	17,500	12,500						
Capital Redemption Reserve				600	600	600						
* Not Audited												

* Not Annualised

Notes:

- The above is an extract of the detailed format of financial results (both standalone and consolidated) for three and six months ended September 30,2020 filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the stock exchange websites www. nseindia.com and www.bseindia.com and also the company's website www.apollohospitals.com.
- The unaudited financial results (Standalone and Consolidated) of Apollo Hospitals Enterprise Limited ("the Company") for the three and six months ended September 30, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on November 10, 2020 and November 11, 2020, respectively and have been subjected to limited review by the statutory auditors.
- For the items referred in sub-clauses (a), (b), (d) and (e) of the Regulation 52(4) of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, the pertinent disclosures have been made to the Stock Exchanges (BSE and NSE) and can be accessed on the URL (www.bseindia.com and www.nseindia.com)
- The Board of Directors, in their meeting held on November 11, 2020 have approved the proposal for executing a definitive Share Purchase Agreement (SPA) for the acquisition of 50% equity stake held by Gleneagles Development PTE Limited, Singapore, in Apollo Gleneagles Hospital Limited, Kolkata ("AGHL"), a joint venture in which the Company holds a 50% equity stake, for a cash consideration of Rs 41,000 lakhs. Pending execution of the said SPA and completion of the other allied conditions, no effect of the acquisition has been given in these financial results.
- The Board has approved the acquisition of additional 1% equity stake in Medics International Life Sciences Limited, a Joint Venture, in which it already holds a 50% equity stake, for a consideration of Rs. 398 lakhs. Pending execution of this transaction, no effect of the same has been given in this financial results.
- The Board of Directors have approved the proposal to raise funds by way of issue of securities through preferential allotment and / or Qualified Institutional Placement (QIP) or any equivalent capital raising method permitted by applicable laws, subject to approval of the shareholders, up to a maximum aggregate limit of Rs. 150,000 lakhs.
- Standalone :**
The Scheme of Arrangement (the Scheme) for transfer of front-end retail pharmacy business included in the standalone pharmacy segment ('divestment business') to Apollo Pharmacies Limited ('APL' or 'Transferee Company'), a wholly owned subsidiary of Apollo Medicals Private Limited ('AMPL') for an overall cash consideration of Rs.52,780 lakhs was approved by the National Company Law Tribunal vide their Order dated August 3, 2020. The Scheme was effective from September 1, 2020 (effective date). As per the Scheme, accounting in the books of the Company is given effect as on the effective date considering the transfer of the divestment business with effect from April 1, 2019 ('appointed date'). Consequently, the net economic benefit transferred from the appointed date till the effective date related to divestment business of Rs. 8,560 lakhs has been included under exceptional items.
Pursuant to the Scheme becoming effective, the Company invested Rs.3,650 lakhs and its ownership interest in AMPL changed to 25.50%, resulting in loss of control with effect from September 1, 2020. Net gain on disposal of divestment business of Rs. 8,450 lakhs has been included under exceptional items.
Retail Pharmacy segment as presented in these standalone financial results includes transactions of the divestment business till the effective date. Post the disposal of divestment business, the Company has identified Pharmacy distribution as a new segment with effect from September 1, 2020. The Company henceforth has Healthcare and Pharmacy Distribution as its operating and reportable segments. Healthcare segment represents hospitals and hospital based pharmacies. Pharmacy distribution segment represents the business of procurement and distribution of pharmaceutical, Fast Moving Consumer Goods (FMCG) and private label products.
The figures for the three and six months ended September 30, 2020 are not comparable with the figures for the previous three months ended June 30, 2020, corresponding three months of the previous period ended September 30, 2019 and the year to date figures of the previous period ended September 30, 2019.

Consolidated :

The Scheme of Arrangement (the Scheme) for transfer of front-end retail pharmacy business included in the standalone pharmacy segment ('divestment business') to Apollo Pharmacies Limited ('APL' or 'Transferee Company'), a wholly owned subsidiary of Apollo Medicals Private Limited ('AMPL') for an overall cash consideration of Rs.52,780 lakhs was approved by the National Company Law Tribunal vide their Order dated August 3, 2020.
Pursuant to the Scheme becoming effective, the Company invested Rs.3,650 lakhs and its ownership interest in AMPL changed to 25.50%, resulting in loss of control with effect from September 1, 2020. Net gain associated with the loss of control of Rs. 3,544 lakhs has been included under Exceptional items. Retail Pharmacy segment as presented in these consolidated financial results includes transactions of the divestment business till the effective date. Post the disposal of the divestment business, the Company has identified Pharmacy distribution as a new segment with effect from September 1, 2020. The Company henceforth has Healthcare and Pharmacy Distribution as its operating and reportable segments. Healthcare segment represents hospitals and hospital based pharmacies. Pharmacy distribution segment represents the business of procurement and distribution of pharmaceutical, Fast Moving Consumer Goods (FMCG) and private label products.

- The Board of Directors at its meeting held on February 13, 2020 approved the proposal for merger of the following wholly owned subsidiary companies with the Company.

* Apollo Home Healthcare (India) Limited and

* Western Hospitals Corporation Private Limited

- The Company has since filed the requisite applications with NCLT seeking dispensing of convening shareholders / creditors meetings of the Company.
- The listed non-convertible debentures of the Company aggregating to Rs. 50,000 lakhs as on September 30, 2020 are secured by way of first charge on the Company's properties and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.

- The Management has considered the possible effects if any that may result from the pandemic relating to COVID-19 on recoverability of receivables, Property, plant & equipment including Capital work in progress and certain investments. The Company has considered internal and external information up to the date of approval of these financial results. Based on the current indicators of future economic conditions, the Company expects to recover the carrying amount of these assets. The actual outcome of these assumptions and estimates may vary in future due to the impact of the pandemic. The Company will continue to monitor any material changes to future economic conditions and the consequent impact on its business if any, and any significant impact of these changes would be recognized in the financial results as and when these material changes to economic conditions arise.

- The proceedings initiated against Imperial Hospitals and Research Centre Limited, a subsidiary company, by the Government of Karnataka alleging, non-compliance of certain conditions associated with the allotment of land, has been stayed by the Honourable High Court of Karnataka on April 27, 2018. Based on legal opinion, the management is of the opinion that it has adequate grounds to demonstrate compliance with applicable conditions and therefore the proceedings are not sustainable. There have been no further developments during this quarter.

Place : Chennai
Date : 11th November, 2020

for APOLLO HOSPITALS ENTERPRISE LIMITED
DR. PRATHAP C REDDY
Executive Chairman

டாக்டர் வி.மோகன் சூளுரை

கனம் டாக்டர்	ஒவ்வொரு உறுப்பினரிடமிருந்தும்
சட்டமன்ற உறுப்பினர்	ஒரு மாநகரத்திலிருந்து
செயல்பாட்டின்படி ஒரு குழு	செல்லும். 1960-ம் ஆண்டு
நிறுவனம் ஆகும்.	சென்றிருந்தால்
வசைத்தொழுவின் சட்டமன்ற உறுப்பினர்	அவ்வளவுக்குள்ளே ஜிஎஸ்சி வரியைப்
இந்தச் சங்கம் இயக்குதலாக	மட்டுமே பெற்றுக் கொள்ளப்படுகிறது.
வெள்குத்துக்கு	இதை மன்றாகச் சட்டமன்ற உறுப்பினர்
வசைத்தொழுவம்	அல்லது இடைத்தரணி ஏதும்
வசைத்தொழுவம் அல்லாம் அல்லாம்.	இல்லை. இல்லாத 800 சட்டமன்ற உறுப்பினர்
உள்ளது. செயற்குப் பயனாக	இருக்கத்தக்க செலவினம் பெற்று
தேவைக்கு 1984-ம் 2288 என்ற	பெற்று செலவாகிறது. செலவினத்திற்கு
முதலில் தொடர்பு கொள்ளுமா?	முதலாக செயல்படப்படுகிறது.
இதில் ஒன்றிரண்டு வசைத் தொழுவம்	பெற்று வசைத் தொழுவம்
பெற்று இவ்வாறு உறுப்பினர்	பெற்று வருகிறது. இதை
பெற்று இவ்வாறு உறுப்பினர்	நாதிபரிசீலிப்படுகிறது.
இருக்கின்றது.	இது பற்றி அரசு 1984-ம் 2288
	எனவாகத் தொடர்பு கொள்கிறது.

<div> <div> Apollo Hospitals Enterprise Limited Corporate Identity Number: 185110TN1579PLC008035 Regd. Office: No. 19 Bishop Gardens, Raja Annamalapuram, Chennai - 28, Tamil Nadu Tel: +91-44-28290956, Fax +91-44-28290356 Email: investor.relations@apollohospitals.com, Website: www.apollohospitals.com </div> <div>  </div> </div>												
Extract of Statement of Unaudited Financial Results for the Three & Six Months Ended September 30, 2020												
Particulars	Standalone						Consolidated					
	Three months ended 30/09/2020	Preceding Three months ended 30/06/2020	Corresponding Three months ended 30/09/2019	Year to date figures for current period ended 30/09/2020	Year to date figures for previous period ended 30/09/2019	Previous year ended 31/03/2020	Three months ended 30/09/2020	Preceding Three months ended 30/06/2020	Corresponding Three months ended 30/09/2019	Year to date figures for current period ended 30/09/2020	Year to date figures for previous period ended 30/09/2019	Previous year ended 31/03/2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total Income from Operations (net)	2,41,934	1,96,321	2,46,752	4,38,244	4,70,146	9,80,534	2,77,204	2,17,922	2,84,425	4,95,125	5,42,600	11,27,377
Net Profit / (Loss) for the period (Before Tax, Exceptional and/or Extraordinary Items)	3,953	(18,592)	14,035	(14,639)	25,117	51,801	3,015	(25,701)	13,365	(23,688)	22,805	45,869
Net Profit / (Loss) for the period (Before Tax, after Exceptional and/or Extraordinary Items)	3,844	(18,592)	14,035	(14,748)	26,117	68,236	6,560	(25,701)	13,365	(20,142)	22,805	65,699
Net Profit / (Loss) for the period after tax (after Exceptional and Extraordinary Items)	3,252	(14,911)	9,060	(11,559)	16,991	47,025	5,899	(22,626)	8,311	(16,727)	13,226	43,780
Total Comprehensive Income for the period (comprising Profit / Loss) for the period (after-tax) and Other Comprehensive Income (after-tax)	2,824	(15,072)	9,029	(12,248)	17,095	47,100	5,549	(22,782)	7,763	(17,232)	12,817	43,120
Paid up Equity Share Capital (Face value of Rs./- each)						6,956						6,956
Other Equity						3,91,897						3,92,609
Earnings Per Share of Rs./- each												
Basic	*2.34	*(10.72)	*6.51	*(8.38)	*12.21	33.80	*4.33	*(14.96)	*6.20	*(10.63)	*10.31	32.70
Diluted	*2.34	*(10.72)	*6.51	*(8.38)	*12.21	33.80	*4.33	*(14.96)	*6.20	*(10.63)	*10.31	32.70
Debt Equity Ratio				0.83	0.96	0.82						
Debt Service Coverage Ratio				0.77	2.53	2.92						
Interest Service Coverage Ratio				2.53	5.82	4.27						
Networth				3,69,495	3,52,858	3,85,570						
Paid up Debt Capital				50,000	50,000	50,000						
Debt:ure Redemption Reserve				12,500	17,500	12,500						
Capital Redemption Reserve				500	600	600						
* Not Annualised												
Notes: 1. The above is an extract of the detailed format of financial results (both standalone and consolidated) for three and six months ended September 30, 2020 filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the stock exchange websites www.nseindia.com and www.bseindia.com and a sc the company's website www.apollohospitals.com . 2. The unaudited financial results (Standalone and Consolidated) of Apollo Hospitals Enterprise Limited ("the Company") for the three and six months ended September 30, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on November 10, 2020 and November 11, 2020, respectively and have been subjected to limited review by the statutory auditors. 3. For the items referred to in sub-clauses (b), (c), (d) and (e) at the Regulation 32(4) of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, the pertinent disclosures have been made to the Stock Exchanges (BSE and NSE) and can be accessed on the URL www.secdisclosure.com and www.nseindia.com . 4. The Board of Directors, in their meeting held on November 11, 2020 have approved the proposal for executing a definitive Share Purchase Agreement (SPA) for the acquisition of 50% equity stake held by Glinagex Development PTE Limited, Singapore, in Apollo Glinagex Hospitals Limited ("AGHL"), a joint venture in which the Company holds a 50% equity stake, for a cash consideration of Rs 41,200 lakhs. Pending execution of the said SPA and completion of the other allied conditions, no effect of the acquisition has been given in these financial results. 5. The Board has approved the acquisition of additional 1% equity stake in Medics International Life Sciences Limited, a Joint Venture, in which it already holds a 50% equity stake, for a consideration of Rs. 398 lakhs. Pending execution of this transaction, no effect of the same has been given in these financial results. 6. The Board of Directors have approved the proposal to raise funds by way of issue of securities through preferential allotment and / or Qualified Institutional Placement (QIP) or any equivalent capital raising method permitted by applicable laws, subject to approval of the shareholders, up to a maximum aggregate limit of Rs. 150,000 lakhs. 7. Standalone : The Scheme of Arrangement (the Scheme) for transfer of front end retail pharmacy business included in the standalone pharmacy segment (divestment business) to Apollo Pharmacies Limited (APL or Transferee Company), a wholly owned subsidiary of Apollo Medicals Private Limited (AMPL) for an overall cash consideration of Rs.32,780 lakhs was approved by the National Company Law Tribunal vide their Order dated August 3, 2020. The Scheme was effective from September 1, 2020 (effective date). As per the Scheme, accounting in the books of the Company is given effect to on the effective date so as to transfer the transfer of the divestment business with effect from April 1, 2019 (appointed date). Consequently, the net economic benefit transferred from the appointed date till the effective date related to divestment business of Rs. 8,550 lakhs has been included under exceptional items. Pursuant to the Scheme becoming effective, the Company invested Rs.3,650 lakhs and its ownership interest in AMPL changed to 25.50%, resulting in loss of control with effect from September 1, 2020. Net gain on disposal of divestment business of Rs. 8,450 lakhs has been included under exceptional items. Retail Pharmacy segment as presented in these standalone financial results includes transactions of the divestment business till the effective date. Post the disposal of divestment business, the Company has identified Pharmacy distribution as a new segment with effect from September 1, 2020. The Company henceforth has Healthcare and Pharmacy Distribution as its operating and reportable segments. Healthcare segment represents hospitals and hospital based pharmaceuticals. Pharmacy distribution segment represents the business of procurement and distribution of pharmaceuticals, Fast Moving Consumer Goods (FMCG) and private label products. The figures for the three and six months ended September 30, 20												

Executive Chairman